Alnylam Begins Phase IIb Study of RSV Therapy

Alnylam previously released data from a phase IIa study of the drug in RSV-infected adult lung transplant patients showing that it was safe and well tolerated. While the data indicated a certain level of efficacy, this demonstration was less robust than many industry watchers had expected.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.